Abstract:AIM: To investigate the biological effects of internal irradiation, and the therapeutic effectiveness was assessed of I-131-labeled anti-epidermal growth factor receptor (EGFR) liposomes, derived from cetuximab, when used as a tumor-targeting carrier in a colorectal cancer mouse model.METHODS: We described the liposomes and characterized their EGFR-targeted binding and cellular uptake in EGFR-overexpressing LS180 colorectal cancer cells. After intra-tumor injections of 74 MBq (740 MBq/ml) I-131-antiEGFR-BSA-PCL, we investigated the biological effects of internal irradiation and the therapeutic efficacy of I-131-antiEGFR-BSA-PCL on colorectal cancer in a male BALB/c mouse model. Tumor size, body weight, histopathology, and SPECT imaging were monitored for 33 d post-therapy.RESULTS: The rapid radioiodine uptake of I-131-anti-EGFR-BSA-PCL and I-131-BSA-PCL reached maximum levels at 4 h after incubation, and the I-131 uptake of I-131-antiEGFR-BSA-PCL was higher than that of I-131-BSAPCL in vitro. The I-131 tissue distribution assay revealed that I-131-antiEGFR-BSA-PCL was markedly taken up by the tumor. Furthermore, a tissue distribution assay revealed that I-131-antiEGFR-BSA-PCL was markedly taken up by the tumor and reached its maximal uptake value of 21.0 +/- 1.01 % ID/g (% ID/g is the percentage injected dose per gram of tissue) at 72 h following therapy; the drug concentration in the tumor was higher than that in the liver, heart, colon, or spleen. Tumor size measurements showed that tumor development was significantly inhibited by treatments with I-131-antiEGFR-BSA-PCL and I-131-BSA-PCL. The volume of tumor increased, and treatment rate with I-131-antiEGFR-BSA-PCL was 124% +/- 7%, lower than that with I-131-BSA-PCL (127% +/- 9%), I-131 (143% +/- 7%), and normal saline (146% +/- 10%). The percentage losses in original body weights were 39% +/- 3%, 41% +/- 4%, 49% +/- 5%, and 55% +/- 13%, respectively. The best survival and cure rates were obtained in the group treated with I-131-antiEGFR-BSA-PCL. The animals injected with I-131-antiEGFR-BSA-PCL and I-131-BSA-PCL showed more uniform focused liposome distribution within the tumor area.CONCLUSION: This study demonstrated the potential beneficial application of I-131-antiEGFR-BSA-PCL for treating colorectal cancer. I-131-antiEGFR-BSA-PCL suppressed the development of xenografted colorectal cancer in nude mice, thereby providing a novel candidate for receptor-mediated targeted radiotherapy.

Evaluation of SPECT/CT Imaging and Internal Therapeutic Effectiveness of 131I-RGD-BSA-PCL in the Lung Cancer Mouse Model

Evaluation of the internal therapeutic effectiveness of 131I-antiEGFR-BSA-PCL in nude mice with colorectal cancer

Antitumor Effect of Nanoparticle 131 I-Labeled Arginine-Glycine-Aspartate-Bovine Serum Albumin-Polycaprolactone in Lung Cancer.

Evaluation of Therapeutic Effectiveness Of131i-Antiegfr-bsa-pcl in a Mouse Model of Colorectal Cancer

The experimental study of radioimmunoimaging and radioimmunotherapy using ~(131)I-labeled anti-progastrin-releasing peptide_((31-98)) monoclonal antibody E-B_5

In vitro and in vivo study on the treatment of non-small cell lung cancer with radionuclide labeled PD-L1 nanobody

Experimental Study of Targeting Therapy of Lung Carcinoma in Mice with 131I Combined Hnrnp B1 Monoclonal Antibody

Targeted Radionuclide Therapy in Patient-Derived Xenografts Using 177Lu-Eb-rgd.

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor

Iodine-125 Interstitial Brachytherapy Reduces Tumor Growth Via Warburg Effect Inhibition in Non-Small Cell Lung Cancer A549 ×Enografts.

Targeting therapeutic effect of radioiodine-labeled anti-EGFR binding nanoparticles on glioblastoma cells

Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice

Therapy of cervical cancer using 131 I-labeled nanoparticles.

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Experimental Study for the Targeting Therapy of Mouse Lung Carcinoma Treated by Anti-hnRNPB1 Monoclonal Antibody with 131I

Development of 177Lu-Eb-rgd Molecular Probe and Its Imaging and Therapy in the Patient-Derived Xenografts of Non-Small Cell Lung Cancer

Therapy of cervical cancer using<sup>131</sup>I-labeled nanoparticles

Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model

Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple-Negative Breast Cancer Using Radiolabeled Anti-Programmed Death-Ligand 1 Monoclonal Antibody

Radionuclide therapy using 131 I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression

Partial volume correction improves theranostic 124I/131I-CLR1404 tumor dosimetry in xenograft models of head and neck cancer